uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial
Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA..
Allegheny Singer Res Inst, Inst Cellular Therapeut, 320 E N Ave, Pittsburgh, PA 15212 USA..
Catholic Univ Louvain, Fac Med, Expt Surg Lab, Brussels, Belgium..
Univ Minnesota, Preclin Res Ctr, Dept Surg, St Paul, MN 55108 USA..
Vise andre og tillknytning
2016 (engelsk)Inngår i: Xenotransplantation, ISSN 0908-665X, E-ISSN 1399-3089, Vol. 23, nr 1, s. 46-52Artikkel i tidsskrift (Fagfellevurdert) Published
Resurstyp
Text
Abstract [en]

In 2009, the International Xenotransplantation Association (IXA) published a consensus document that provided guidelines and recommendations (not regulations) for those contemplating clinical trials of porcine islet transplantation. These guidelines included the IXA's opinion on what constituted rigorous pre-clinical studies using the most relevant animal models and were based on non-human primate testing. We now report our discussion following a careful review of the 2009 guidelines as they relate to pre-clinical testing. In summary, we do not believe there is a need to greatly modify the conclusions and recommendations of the original consensus document. Pre-clinical studies should be sufficiently rigorous to provide optimism that a clinical trial is likely to be safe and has a realistic chance of success, but need not be so demanding that success might only be achieved by very prolonged experimentation, as this would not be in the interests of patients whose quality of life might benefit immensely from a successful islet xenotransplant. We believe these guidelines will be of benefit to both investigators planning a clinical trial and to institutions and regulatory authorities considering a proposal for a clinical trial. In addition, we suggest consideration should be given to establishing an IXA Clinical Trial Advisory Committee that would be available to advise (but not regulate) researchers considering initiating a clinical trial of xenotransplantation.

sted, utgiver, år, opplag, sider
2016. Vol. 23, nr 1, s. 46-52
Emneord [en]
diabetes mellitus, islets, non-human primates, pig - xenotransplantation
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-288638DOI: 10.1111/xen.12226ISI: 000372726500006PubMedID: 26916706OAI: oai:DiVA.org:uu-288638DiVA, id: diva2:926070
Tilgjengelig fra: 2016-05-04 Laget: 2016-04-28 Sist oppdatert: 2017-11-30bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Korsgren, Olle

Søk i DiVA

Av forfatter/redaktør
Korsgren, Olle
Av organisasjonen
I samme tidsskrift
Xenotransplantation

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 498 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf